Table 5.

Prognosis of each group (median + sd, months).

		N-PSE, mo
	N-PSE, mo	N-PSE-M	N-PSE-S	PSE, mo	P1	P2
OS	18.97 ± 2.35	18.97 ± 2.01	6.50 ± 13.50	24.47 ± 3.68	0.110	0.275
PFS	5.53 ± 2.06	5.53 ± 2.31	4.40 ± 3.77	12.63 ± 4.98	0.031	0.072
Intrahepatic in situ progression	9.53 ± 2.08	9.53 ± 2.06	6.50 ± 3.90	18.53 ± 6.34	0.056	0.148
Intrahepatic neoplastic metastasis	10.17 ± 2.19	12,77 ± 2.86	6.50 ± 2.89	22.30 ± 6.94	0.051	0.149
Extrahepatic progression	12.67 ± 4.97	12.67 ± 3.65	4.40 ± 9.85	22.10 ± 0.84	0.028	0.088

N-PSE = non-partial splenic embolization, OS = overall survival, PFS = progression-free survival, PSE = partial splenic embolization, sd = standard deviation.

P1 comparison between large groups; P2 comparison between subgroups; P < .05 is defined as a significant difference.